Details for Patent: 10,959,972

Which drugs does patent 10,959,972 protect, and when does it expire?

Patent 10,959,972 protects TECFIDERA and is included in one NDA.

This patent has thirty-five patent family members in thirteen countries.

Summary for Patent: 10,959,972

Patent landscape, scope, and claims:

Title:	Methods of treating multiple sclerosis
Abstract:	Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
Inventor(s):	Novas; Mark (Lexington, MA), Zhang; Rui (Ray) (Sharon, MA)
Assignee:	BIOGEN MA INC. (Cambridge, MA)
Application Number:	16/173,723
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,959,972

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013	AB	RX	Yes	No	10,959,972					METHOD OF TREATING MULTIPLE SCLEROSIS
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-002	Mar 27, 2013	AB	RX	Yes	Yes	10,959,972					METHOD OF TREATING MULTIPLE SCLEROSIS

International Family Members for US Patent 10,959,972

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015350213
Australia	2020239734
Australia	2021269298
Australia	2024203437